Livionex develops proprietary metal‑ion modulating therapies and has launched LIVFRESH Dental Gel, a dentist‑recommended product clinically shown to remove plaque 250% better than a market leading toothpaste and currently under FDA evaluation to treat gingivitis and periodontitis. The company is advancing an eye‑drop candidate toward a Phase 2C study aimed at improving vision in early‑to‑moderate cataract patients and has a transdermal lotion program intended to prevent herpes simplex eruptions, supported by NIH and Department of Defense grants. Funding from the announced round will be used to accelerate development of treatments for gum disease, cataracts, and HSV and to drive market penetration of LIVFRESH in the U.S. and Asian markets. Livionex’s products use safe, edible ingredients on the FDA GRAS list and are based on its proprietary technology that modulates metal ions linked to oxidative stress, inflammation, and biofilms. The company was founded in 2009 and is headquartered in Los Gatos, CA. Livionex reports being cash‑flow positive, has over 44 patent filings globally, and is targeting an IPO in 2021.

Total raised

$4M

Funding rounds

1

Latest round

Series A

Latest activity

May 2019